超“UCSF标准”肝细胞癌肝移植术前经肝动脉化疗栓塞的疗效

doi:10.16139/j.1007-9610.2018.03.012

摘要/Abstract

摘要： 目的: 评估经肝动脉化疗栓塞（TACE）在超“UCSF标准”肝细胞癌（HCC）肝移植术前治疗的安全性及疗效。方法: 回顾性分析2003年1月至2013年3月在本院行肝移植治疗的83例超“UCSF标准”的成年HCC病人临床资料,根据术前是否采取TACE治疗分为TACE治疗组（63例）与对照组（20例）。比较两组病人术后急性排异、胆道并发症和血管并发症发生率、无瘤生存率及总生存率。结果: TACE治疗组在肝移植术前平均进行了（2.0±1.3）次TACE疗程,末次治疗至肝移植的平均时间为（15.7±8.4） d。TACE治疗组与对照组相比,在肝移植术后急性排异、肝动脉栓塞和胆道并发症发生率差异无统计学意义（P>0.05）。TACE治疗组无瘤生存率及总生存率明显优于对照组（P<0.05）。分层分析表明,TACE治疗后获得完全反应或部分反应的HCC病人行肝移植1、3、5年无瘤生存率及总生存率明显高于TACE治疗后无反应组（P<0.05）。TACE治疗后肿瘤降期至“UCSF标准”的HCC病人行肝移植1、3、5年无瘤生存率及总生存率明显高于降期治疗后未达到“UCSF标准”的病人（P<0.05）。结论: 肝移植术前TACE治疗可延长病人无瘤生存及总生存时间。肝移植术前TACE降期治疗安全,仅1例发生肝动脉栓塞并发症。

关键词: 肝移植, 肝细胞癌, 经动脉化疗栓塞, 降期治疗

Abstract: Objective: To assess the safety and effectiveness of preliver transplantation transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) beyond UCSF criteria. Methods: We retrospectively analyzed the clinical data of 83 patients with HCC beyond UCSF criteria, who were divided into TACE group and control group. The postoperative acute rejection, biliary complications, vascular complications, tumor free survival rate and overall survival rate between two groups were compared. Results: There were (2.0±1.3) preliver transplantation TACE procedures with the period of (15.7±8.4) d between final TACE treatment and liver transplantation. There was no significant difference in postoperative acute rejection, biliary complications and hepatic artery embolism between TACE group and control group(P>0.05). The tumor free survival rate and overall survival rate in TACE group were significantly higher than those in control group (P<0.05). Stratification analysis revealed that the 1-, 3-, 5-year tumor free survival rate and overall survival rate of the patients with complete response or partial response were much higher than those of the patients without response(P<0.05). The 1-, 3-, 5-year tumor free survival rate and overall survival rate were significantly higher in the patients with HCC which satisfied UCSF criteria after TACE than those in the patients with HCC still beyond UCSF criteria(P<0.05). Conclusions: Preliver transplantation TACE can prolong tumor free survival time and overall survival time, and is safe with only one case of hepatic artery embolism.

Key words: Liver transplantation, Hepatocellular carcinoma, Tansarterial chemoembolization, Down-staging treatment

中图分类号:

R735.7

佟辉, 张家强, 祝哲诚, 彭承宏, 李涛. 超“UCSF标准”肝细胞癌肝移植术前经肝动脉化疗栓塞的疗效[J]. 外科理论与实践, 2018, 23(03): 241-246.

TONG Hui, ZHANG Jiaqiang, ZHU Zhecheng, PENG Chenghong, LI Tao. Effectiveness of preliver transplantation transarterial chemoembolization therapy in treatment of hepatocellular carcinoma beyond UCSF criteria[J]. Journal of Surgery Concepts & Practice, 2018, 23(03): 241-246.

参考文献

[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] Piñero F, Costa P, Boteon YL, et al.Results of liver transplantation for hepatocellular carcinoma in a multicenter Latin American cohort study[J]. Ann Hepatol,2018,17(2):256-267.
[3] Mehta N, Guy J, Frenette CT, et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan Criteria: A multicenter study[J]. Clin Gastroenterol Hepatol,2017,pii:S1542-3565(17)31410-31416.
[4] Kim Y, Stahl CC, Makramalla A, et al.Downstaging the-rapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery,2017,162(6):1250-1258.
[5] Kang WH, Hwang S, Song GW, et al.Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma[J]. Liver Transpl,2017,23(6):781-790.
[6] Lei JY, Zhong JJ, Luo YF, et al.Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation[J]. Oncotarget,2017,8(53):91328-91342.
[7] Mazzaferro V, Regalia E, Doci R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med,1996,334(11):693-699.
[8] Yao FY, Ferrell L, Bass NM, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology,2001,33(6):1394-1403.
[9] 樊嘉, 周俭, 徐泱, 等. 肝癌肝移植适应证的选择:上海复旦标准[J]. 中华医学杂志,2006,86(18):1227-1231.
[10] 徐骁, 杨家印, 钟林, 等. 肝癌肝移植“杭州标准”的多中心应用研究——1163例报道[J]. 中华器官移植杂志,2013,34(9):524-527.
[11] Hodavance MS, Vikingstad EM, Griffin AS, et al.Effectiveness of transarterial emolization of hepatocellular carcinoma as a bridge to transplantation[J]. J Vasc Interv Radiol,2016,27(1):39-45.
[12] Thuluvath PJ, Guidinger MK, Fung JJ, et al.Liver transplantation in the United States[J]. Am J Transplant,2010,10(4 Pt 2):1003-1019.
[13] Graziadei IW, Sandmueller H, Waldenberger P, et al.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome[J]. Liver Transpl,2003,9(6):557-563.
[14] Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al.Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma[J]. Liver Transpl,2005,11(7):767-775.
[15] Eswaran SL, Pierce K, Weaver F, et al.Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times[J]. Angiology,2012,63(3):206-212.
[16] Seehofer D, Nebrig M, Denecke T, et al.Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis[J]. Clinical Transplantation,2012,26(5):764-774.
[17] Schaudt A, Kriener S, Schwarz W, et al.Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis[J]. Clinical Transplantation,2009,23(Suppl 21):61-67.
[18] Jianyong L, Jinjing Z, Lunan Y, et al.Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma[J]. Sci Rep,2017,7:41624.
[19] Si T, Chen Y, Ma D, et al.Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol,2017,32(7):1286-1294.
[20] Kulik L, Heimbach JK, Zaiem F, et al.Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis[J]. Hepatology,2018,67(1):381-400.
[21] Al Sebayel MI, Elsiesy H, Al-Hamoudi WA, et al.Effect of downstaging and bridging of hepatocellular carcinoma on survival following liver transplant: a single center experience[J]. Exp Clin Transplant,2017,15(suppl 2):7-11.
[22] Ince V, Ersan V, Karakas S, et al.Does preoperative transarterial chemoembolization for hepatocellular carcinoma increase the incidence of hepatic artery thrombosis after living-donor liver transplant?[J]. Exp Clin Transplant,2017,15(supp1 2):21-24.
[23] Sneiders D, Houwen T, Pengel LHM, et al.Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation[J]. Transplantation,2018,102(1):88-96.
[24] Kallini JR, Gabr A, Ali R, et al.Pretransplant intra-arterial liver-directed therapy does not increase the risk of hepatic arterial complications in liver transplantation: a single-center 10-year experience[J]. Cardiovasc Intervent Radiol,2018,41(2):231-238.